CY2230B1 - Stable pharmaceutical compositions containing hybrid alpha-interferon - Google Patents

Stable pharmaceutical compositions containing hybrid alpha-interferon

Info

Publication number
CY2230B1
CY2230B1 CY0100020A CY0100020A CY2230B1 CY 2230 B1 CY2230 B1 CY 2230B1 CY 0100020 A CY0100020 A CY 0100020A CY 0100020 A CY0100020 A CY 0100020A CY 2230 B1 CY2230 B1 CY 2230B1
Authority
CY
Cyprus
Prior art keywords
interferon
pharmaceutical compositions
compositions containing
hybrid alpha
stable pharmaceutical
Prior art date
Application number
CY0100020A
Other languages
English (en)
Inventor
Nicholas Lowther
John Douglas Allen
Colin Howes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939316849A external-priority patent/GB9316849D0/en
Priority claimed from GB9405879A external-priority patent/GB9405879D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2230B1 publication Critical patent/CY2230B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CY0100020A 1993-08-13 2001-07-30 Stable pharmaceutical compositions containing hybrid alpha-interferon CY2230B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939316849A GB9316849D0 (en) 1993-08-13 1993-08-13 Pharmaceutical compositions
GB9405879A GB9405879D0 (en) 1994-03-24 1994-03-24 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CY2230B1 true CY2230B1 (en) 2003-04-18

Family

ID=26303371

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0100020A CY2230B1 (en) 1993-08-13 2001-07-30 Stable pharmaceutical compositions containing hybrid alpha-interferon

Country Status (19)

Country Link
US (1) US5609868A (pt)
EP (1) EP0641567B1 (pt)
JP (1) JP3745395B2 (pt)
KR (1) KR100351495B1 (pt)
AT (1) ATE190498T1 (pt)
AU (1) AU679233B2 (pt)
CA (1) CA2129921C (pt)
CY (1) CY2230B1 (pt)
DE (1) DE69423402T2 (pt)
DK (1) DK0641567T3 (pt)
ES (1) ES2144034T3 (pt)
FI (1) FI111222B (pt)
GR (1) GR3033239T3 (pt)
HU (1) HU224613B1 (pt)
IL (1) IL110566A (pt)
NO (1) NO315843B1 (pt)
NZ (1) NZ264218A (pt)
PT (1) PT641567E (pt)
TW (1) TW249202B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102236A1 (en) * 1994-12-08 2002-08-01 Taylor Peter William Liposomal interferon hybrid compositions
ES2224290T5 (es) * 1996-12-24 2012-03-12 Biogen Idec Ma Inc. Formulaciones l�?quidas estables de interferón.
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
KR19990075253A (ko) * 1998-03-18 1999-10-15 성재갑 약학적으로 안정한 인터페론 제
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
ES2167189B1 (es) 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
DE60139339D1 (de) * 2000-11-07 2009-09-03 Novartis Vaccines & Diagnostic Stabilisierte interferonzusammensetzungen
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
EP1909822B1 (en) * 2005-06-29 2013-09-25 Yeda Research And Development Co., Ltd. Recombinant interferon alpha 2 (ifn alpha 2) mutants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196823A (ja) * 1983-04-20 1984-11-08 Sunstar Inc 皮膚および粘膜の真菌症治療用外用剤
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
ES8705761A1 (es) * 1985-03-25 1987-05-16 Schering Corp Un metodo para preparar una formulacion liofilizada y estabilizada de gamma interferon
DE3685996T2 (de) * 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer

Also Published As

Publication number Publication date
TW249202B (pt) 1995-06-11
PT641567E (pt) 2000-08-31
KR100351495B1 (ko) 2003-02-19
CA2129921A1 (en) 1995-02-14
GR3033239T3 (en) 2000-09-29
FI111222B (fi) 2003-06-30
DE69423402T2 (de) 2000-08-03
EP0641567A1 (en) 1995-03-08
KR950005325A (ko) 1995-03-20
AU679233B2 (en) 1997-06-26
HUT68692A (en) 1995-07-28
AU6893994A (en) 1995-02-23
DE69423402D1 (de) 2000-04-20
IL110566A0 (en) 1995-01-24
JP3745395B2 (ja) 2006-02-15
CA2129921C (en) 2006-12-05
EP0641567B1 (en) 2000-03-15
DK0641567T3 (da) 2000-08-14
IL110566A (en) 1999-12-22
US5609868A (en) 1997-03-11
NO315843B1 (no) 2003-11-03
FI943705A0 (fi) 1994-08-10
FI943705A (fi) 1995-02-14
JPH07145070A (ja) 1995-06-06
NO942983L (no) 1995-02-14
HU224613B1 (hu) 2005-11-28
ATE190498T1 (de) 2000-04-15
ES2144034T3 (es) 2000-06-01
NZ264218A (en) 1995-07-26
NO942983D0 (no) 1994-08-12
HU9402356D0 (en) 1994-10-28

Similar Documents

Publication Publication Date Title
MY113806A (en) Antiparasitic marcfortines and paraherquamides
HU9302329D0 (en) 7-(substituted)-9-|(substituted glycyl)-amino¨-6-desmethyl-6-desoxy-tetracyclines, pharmaceutical preparatives containing them and methods for producing them
GR3030167T3 (en) Amidino derivatives useful as nitric oxide synthase inhibitors
IL106677A0 (en) Novel 7-(substituted)-8-(substituted-9-(substituted amino)-6-demethyl-6-deoxytetracyclines
IL106673A (en) 7-(substituted)-9- £(substituted glycyl) amido|-6- demethyl-6- deoxytetracyclines
PH30006A (en) 9-¬(Substituted glycol)amido¾-6.demethyl-6-deoxytetra-cyclines
IL109720A (en) N-alkylthio polyamine derivatives and radioprotective compositions containing them
GR3033239T3 (en) Stable pharmaceutical compositions containing hybrid alpha-interferon.
GB8900525D0 (en) Liquid detergent composition containing enzyme and enzyme stabilization system
EP1104761A4 (en) FLUORESCENT MARKERS
IL111275A (en) Derivatives of 6-demethylgalanthamine, their mono-and di-esters and pharmaceutical compositions containing them
ZA883444B (pt)
ES2146606T3 (es) Metodo para limpiar alfombras.
EP0974347A4 (en) ANTIVIRAL AGENTS
PH27384A (en) Hair treatment compositions
IL105669A0 (en) Dithiolanylglycine-containing hiv protease inhibitors of the hydroxyethylene isostere type,their preparation and pharmaceutical compositions containing them
NZ279396A (en) Octahydro-6-hetring[2,1-a][2]benzazepine disulphide derivatives
EP0978277A4 (en) ANTI-RHUMATISMAL AGENTS
DK0623620T3 (da) 5-HT3-pyrrolopyrazinderivater
GR3022546T3 (en) Inositol phosphate analogues as calcium-antagonistic substances
GR3023939T3 (en) (Thia) cycloalkyl(b)indoles, process of their preparation and compositions containing it.
EP0994111A4 (en) TETRAHYDROFURANNE DERIVATIVES